Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aralez Pharmaceuticals Inc.ARLZ · Entity 165961 | President & Chief Business Off | June 04, 2018 | June 06, 2018 |
| KALA BIO, Inc.KALA · Entity 7964 | Director | June 15, 2025 | June 18, 2025 |
| MetaVia Inc.MTVA · Entity 7947 | Director | June 08, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aralez Pharmaceuticals Inc.
Report date June 04, 2018 · Filed June 06, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, without par valueSEC Table I · non-derivative | Direct | 1,183,419 |
Reported balance
After 2018-06-04 transaction · row 1
1 source rowRow 1 · 2018-06-04 · Sale · Disposed 156,573 · Balance 1,183,419 F1: This represents shares sold by the issuer on behalf of the reporting person pursuant to an instruction made in accordance with Rule 10b5-1 for payment of withholding tax liability incurred upon the vesting of 369,168 restricted stock units, which were previously granted on June 3, 2015 and which vested on June 3, 2018. F2: This transaction was executed in multiple trades at prices ranging from $0.3700 to $0.3803. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: This represents shares sold by the issuer on behalf of the reporting person pursuant to an instruction made in accordance with Rule 10b5-1 for payment of withholding tax liability incurred upon the vesting of 369,168 restricted stock units, which were previously granted on June 3, 2015 and which vested on June 3, 2018.
F2: This transaction was executed in multiple trades at prices ranging from $0.3700 to $0.3803. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
KALA BIO, Inc.
Report date June 15, 2025 · Filed June 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,972 |
Reported balance
After 2025-06-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-06-15 · Grant · Acquired 3,050 · Balance 16,972 F1: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026. F2: Includes 8,061 unvested RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.30 · Expires 2035-06-14 | Direct | 6,850 |
Reported balance
After 2025-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-15 · Grant · Acquired 6,850 · Balance 6,850 F3: This option was granted on June 15, 2025 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026.
F2: Includes 8,061 unvested RSUs.
F3: This option was granted on June 15, 2025 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026.
MetaVia Inc.
Report date June 08, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,339 |
Reported balance
After 2026-06-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 17,186 · Balance 21,339 F1: Represents a grant of restricted stock units issued to the Reporting Person under the Issuer's Amended and Restated 2022 Equity Incentive Plan, which vests on the earlier of June 8, 2027 or the day immediately prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuing service on the applicable vesting date. In accordance with the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Policy"), the Reporting Person elected to defer receipt of the shares of common stock upon the vesting of the RSUs until the earlier of the date that is (i) immediately prior to a Change in Control (as described in the Policy), or (ii) within 60 days following the Reporting Person's retirement or other separation from service with the Issuer or death, whichever is earlier. F2: The total number of securities beneficially owned has been adjusted to reflect the Issuer's completion of a 1-for-11 reverse stock split on December 4, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units issued to the Reporting Person under the Issuer's Amended and Restated 2022 Equity Incentive Plan, which vests on the earlier of June 8, 2027 or the day immediately prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuing service on the applicable vesting date. In accordance with the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Policy"), the Reporting Person elected to defer receipt of the shares of common stock upon the vesting of the RSUs until the earlier of the date that is (i) immediately prior to a Change in Control (as described in the Policy), or (ii) within 60 days following the Reporting Person's retirement or other separation from service with the Issuer or death, whichever is earlier.
F2: The total number of securities beneficially owned has been adjusted to reflect the Issuer's completion of a 1-for-11 reverse stock split on December 4, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2026 Filed Jun 8, 2026 22:30 UTC | MetaVia Inc. MTVA · Entity 7947 | GrantCommon Stock | 17,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-071471 · tm2617186-2_4seq1.xml · nonDerivative · entry 1 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,339 F1 · shares: Represents a grant of restricted stock units issued to the Reporting Person under the Issuer's Amended and Restated 2022 Equity Incentive Plan, which vests on the earlier of June 8, 2027 or the day immediately prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuing service on the applicable vesting date. In accordance with the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Policy"), the Reporting Person elected to defer receipt of the shares of common stock upon the vesting of the RSUs until the earlier of the date that is (i) immediately prior to a Change in Control (as described in the Policy), or (ii) within 60 days following the Reporting Person's retirement or other separation from service with the Issuer or death, whichever is earlier. F2 · balance_after: The total number of securities beneficially owned has been adjusted to reflect the Issuer's completion of a 1-for-11 reverse stock split on December 4, 2025. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 20:01 UTC | MetaVia Inc. MTVA · Entity 7947 | GrantCommon Stock | 28,147 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-064706 · tm2519510-2_4seq1.xml · nonDerivative · entry 1 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,699 F1 · shares: Represents a grant of restricted stock units ("RSUs") issued to the Reporting Person under the Issuer's Amended and Restated 2022 Equity Incentive Plan, which vests on the earlier of June 30, 2026 or the day immediately prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuing service on the applicable vesting date. In accordance with the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Policy"), the Reporting Person elected to defer receipt of the shares of common stock upon the vesting of the RSUs until the earlier of the date that is (i) immediately prior to a Change in Control (as described in the Policy), or (ii) within 60 days following the Reporting Person's retirement or other separation from service with the Issuer or death, whichever is earlier. Read SEC document |
| June 15, 2025 Filed Jun 18, 2025 00:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 6,850 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0001415889-25-017611 · form4-06172025_080601.xml · derivative · entry 2 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,850 Underlying: Common Stock · 6,850 shares Expires 2035-06-14 F3 · derivative.exercise_date: This option was granted on June 15, 2025 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026. Read SEC document |
| June 15, 2025 Filed Jun 18, 2025 00:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantCommon Stock | 3,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017611 · form4-06172025_080601.xml · nonDerivative · entry 1 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,972 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 15, 2026 or (ii) the date of the first annual meeting of stockholders occurring in 2026. F2 · balance_after: Includes 8,061 unvested RSUs. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 00:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 3,900 | $0.00 Strike: $6.18 | $0.00 |
DisclosureSEC source: 0001415889-24-016570 · form4-06122024_080605.xml · derivative · entry 2 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,900 Underlying: Common Stock · 3,900 shares Expires 2034-06-10 F3 · derivative.exercise_date: This option was granted on June 11, 2024 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 00:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantCommon Stock | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016570 · form4-06122024_080605.xml · nonDerivative · entry 1 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,922 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 11, 2025 or (ii) the date of the first annual meeting following June 11, 2024. F2 · balance_after: Includes 10,864 unvested RSUs. Read SEC document |
| June 07, 2024 Filed Jun 7, 2024 23:25 UTC | MetaVia Inc. NRBO · Entity 7947 | GrantCommon Stock | 5,051 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-069786 · tm2416741-4_4seq1.xml · nonDerivative · entry 1 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,552 F1 · shares: Represents a grant of restricted stock units ("RSUs") issued to the Reporting Person under the Issuer's 2022 Equity Incentive Plan, which vests on the earlier of June 7, 2025 or the day immediately prior to the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continuing service on the applicable vesting date. In accordance with the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Policy"), the Reporting Person elected to defer receipt of the shares of common stock upon the vesting of the RSUs until the earlier of the date that is (i) immediately prior to a Change in Control (as described in the Policy), or (ii) within 60 days following the Reporting Person's retirement or other separation from service with the Issuer or death, whichever is earlier. F2 · balance_after: The total number of securities beneficially owned has been adjusted to reflect the Issuer's completion of a 1-for-8 reverse stock split on December 20, 2023. Read SEC document |
| July 27, 2023 Filed Jul 28, 2023 10:19 UTC | MetaVia Inc. NRBO · Entity 7947 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-084992 · tm2321997-2_4seq1.xml · nonDerivative · entry 2 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · shares: Represents a grant of restricted stock units ("RSUs") issued to the reporting person under the Issuer's 2022 Equity Incentive Plan. Per the terms of the Amended and Restated Non-Employee Director Compensation Policy, the reporting person elected to defer receipt of the shares of common stock upon the vesting of the RSUs until the earlier of the date that is (i) immediately prior to a Change in Control (as described in the Policy), or (ii) within 60 days following the reporting person's retirement or other separation form service with the Issuer or death, whichever is earlier. F3 · shares: Vests on the earlier of July 27, 2024 or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to continuing service. Read SEC document |
| July 27, 2023 Filed Jul 28, 2023 10:19 UTC | MetaVia Inc. NRBO · Entity 7947 | GrantCommon Stock | 87,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-084992 · tm2321997-2_4seq1.xml · nonDerivative · entry 1 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,500 F1 · shares: Represents a grant of restricted stock units ("RSUs") issued to the reporting person under the Issuer's 2022 Equity Incentive Plan. Per the terms of the Amended and Restated Non-Employee Director Compensation Policy, the reporting person elected to defer receipt of the shares of common stock upon the vesting of the RSUs until the earlier of the date that is (i) immediately prior to a Change in Control (as described in the Policy), or (ii) within 60 days following the reporting person's retirement or other separation form service with the Issuer or death, whichever is earlier. F2 · shares: 50% of the RSUs vested immediately, and the remainder will vest in two equal installments on each subsequent anniversary of the date of grant, subject to continuing service. Read SEC document |
| June 22, 2023 Filed Jun 24, 2023 00:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 3,150 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001415889-23-010288 · form4-06232023_080619.xml · derivative · entry 4 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,150 Underlying: Common Stock · 3,150 shares Expires 2033-06-21 F6 · derivative.exercise_date: This option was granted on June 22, 2023 and vests as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023. Read SEC document |
| June 22, 2023 Filed Jun 24, 2023 00:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 10,020 | $0.00 Strike: $14.56 | $0.00 |
DisclosureSEC source: 0001415889-23-010288 · form4-06232023_080619.xml · derivative · entry 3 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,020 Underlying: Common Stock · 10,020 shares Expires 2033-06-21 F5 · derivative.exercise_date: This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter. Read SEC document |
| June 22, 2023 Filed Jun 24, 2023 00:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantCommon Stock | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-010288 · form4-06232023_080619.xml · nonDerivative · entry 2 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,172 F3 · security: Grant of RSUs under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 100% of the shares underlying the grant on the earlier of (i) June 22, 2024 or (ii) the date of the first annual meeting following June 22, 2023. F4 · balance_after: Includes 12,172 unvested RSUs. Read SEC document |
| June 22, 2023 Filed Jun 24, 2023 00:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantCommon Stock | 7,515 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-010288 · form4-06232023_080619.xml · nonDerivative · entry 1 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,772 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026. F2 · balance_after: Includes 10,772 unvested RSUs. Read SEC document |
| May 31, 2023 Filed Jun 3, 2023 00:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | Disposition to issuerStock Option (right to buy) · Derivative | 1,000 | Not disclosed Strike: $18.00 | Not disclosed |
DisclosureSEC source: 0001415889-23-009140 · form4-06022023_080632.xml · derivative · entry 5 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires 2032-06-15 F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 1,197 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 1,000 RSUs that vest 100% on May 31, 2025, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock. F7 · derivative.exercise_date: The cancelled option was granted on June 16, 2022 and provided for vesting as to 100% of the shares underlying the option on the earlier of (i) June 16, 2023 or (ii) the date of the first annual meeting following June 16, 2022. F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. Read SEC document |
| May 31, 2023 Filed Jun 3, 2023 00:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | Disposition to issuerStock Option (right to buy) · Derivative | 420 | Not disclosed Strike: $267.50 | Not disclosed |
DisclosureSEC source: 0001415889-23-009140 · form4-06022023_080632.xml · derivative · entry 4 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 420 shares Expires 2029-06-04 F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 1,197 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 1,000 RSUs that vest 100% on May 31, 2025, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock. F6 · derivative.exercise_date: The cancelled option was granted on June 5, 2019 and provided for vesting with respect to 1/12th of the shares underlying the option at the end of each successive one-month period thereafter. F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. Read SEC document |
| May 31, 2023 Filed Jun 3, 2023 00:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | Disposition to issuerStock Option (right to buy) · Derivative | 259 | Not disclosed Strike: $686.50 | Not disclosed |
DisclosureSEC source: 0001415889-23-009140 · form4-06022023_080632.xml · derivative · entry 3 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 259 shares Expires 2028-06-11 F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 1,197 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 1,000 RSUs that vest 100% on May 31, 2025, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock. F5 · derivative.exercise_date: The cancelled option was granted on June 12, 2018 and provided for vesting in equal monthly installments until the one-year anniversary of the date of grant and was subject to vest automatically as to 100% of the unvested portion of such option upon specified change in control events. F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. Read SEC document |
| May 31, 2023 Filed Jun 3, 2023 00:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | Disposition to issuerStock Option (right to buy) · Derivative | 518 | Not disclosed Strike: $1,154.00 | Not disclosed |
DisclosureSEC source: 0001415889-23-009140 · form4-06022023_080632.xml · derivative · entry 2 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 518 shares Expires 2027-09-28 F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 1,197 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 1,000 RSUs that vest 100% on May 31, 2025, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The cancelled option was granted on September 28, 2017 and provided for vesting with respect to 1/3rd of the shares on the first anniversary of the grant date and with respect to an additional 1/36th of the shares on each monthly anniversary thereafter and was subject to vest automatically as to 100% of the unvested portion of such option upon specified change in control events. F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. Read SEC document |
| May 31, 2023 Filed Jun 3, 2023 00:00 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantCommon Stock | 2,197 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-009140 · form4-06022023_080632.xml · nonDerivative · entry 1 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,257 F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 1,197 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 1,000 RSUs that vest 100% on May 31, 2025, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock. F2 · balance_after: Includes 3,257 unvested or deferred RSUs. Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:45 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001415889-22-006749 · form4-06172022_040601.xml · derivative · entry 1 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: This option was granted on June 16, 2022 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 16, 2023 or (ii) the date of the first annual meeting following June 16, 2022. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 21:21 UTC | MetaVia Inc. NRBO · Entity 7947 | GrantNonstatutory Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001104659-22-070219 · tm2218193-1_4seq1.xml · derivative · entry 1 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: Vests on the earlier of June 9, 2023 or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to continuing service. Read SEC document |
| September 02, 2021 Filed Sep 3, 2021 15:43 UTC | MetaVia Inc. NRBO · Entity 7947 | GrantNonstatutory Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0001596771-21-000049 · primary_doc.xml · derivative · entry 1 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-09-01 F1 · derivative.exercise_date: Vests in 36 approximately equal consecutive monthly increments, commencing on the one-month anniversary of the date of grant, so that all of the options will be vested on the 36-month anniversary of the date of grant. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 21:30 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-003121 · form4-06212021_050611.xml · nonDerivative · entry 1 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued service with the Issuer, the RSUs will vest as to 100% of the shares underlying the RSUs on the earlier of (i) June 17, 2022 or (ii) the date of the first annual meeting following June 17, 2021. F2 · balance_after: Includes 25,000 unvested RSUs. Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 01:36 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantCommon Stock | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-078287 · a4.xml · nonDerivative · entry 1 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right two receive one share of the Issuer's common stock. Subject to the reporting person's continued service with the Issuer, the RSUs will vest as to 100% of the shares underlying the RSUs on the earlier of (i) June 25, 2021 or (ii) the date of the first annual meeting following June 25, 2020. F2 · balance_after: Includes 28,000 unvested RSUs. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 20:01 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001104659-19-034521 · a4.xml · derivative · entry 1 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2029-06-04 F1 · derivative.exercise_date: This option was granted on June 5, 2019 and vests with respect to 1/12th of the shares underlying the option at the end of each successive one-month period thereafter. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 20:47 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 12,960 | $0.00 Strike: $13.73 | $0.00 |
DisclosureSEC source: 0001179110-18-008527 · edgar.xml · derivative · entry 1 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,960 Underlying: Common Stock · 12,960 shares Expires 2028-06-11 F1 · derivative.exercise_date: This option was granted on June 12, 2018 and vests in equal monthly installments until the one-year anniversary of the date of grant and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 21:00 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | SaleCommon Shares, without par value | 156,573 | $0.37 | $58,589.62 |
DisclosureSEC source: 0001104659-18-038619 · a4.xml · nonDerivative · entry 1 KOVEN ANDREW I · CIK 0001258673 · President & Chief Business Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,183,419 F1 · kind: This represents shares sold by the issuer on behalf of the reporting person pursuant to an instruction made in accordance with Rule 10b5-1 for payment of withholding tax liability incurred upon the vesting of 369,168 restricted stock units, which were previously granted on June 3, 2015 and which vested on June 3, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $0.3700 to $0.3803. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 14, 2018 Filed May 16, 2018 23:50 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | SaleCommon Shares, without par value | 13,964 | $0.52 | $7,261.28 |
DisclosureSEC source: 0001104659-18-033906 · a4.xml · nonDerivative · entry 1 KOVEN ANDREW I · CIK 0001258673 · President & Chief Business Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,339,992 F1 · kind: This represents shares sold by the issuer on behalf of the reporting person pursuant to an instruction made in accordance with Rule 10b5-1 for payment of withholding tax liability incurred upon the vesting of 36,396 restricted stock units, which were previously granted on May 11, 2017 and which vested on May 11, 2018. Read SEC document |
| March 19, 2018 Filed Mar 21, 2018 21:16 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | SaleCommon Shares, without par value | 9,739 | $1.70 | $16,556.30 |
DisclosureSEC source: 0001104659-18-019363 · a4.xml · nonDerivative · entry 1 KOVEN ANDREW I · CIK 0001258673 · President & Chief Business Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,353,956 F1 · kind: This represents shares sold by the issuer on behalf of the reporting person pursuant to an instruction made in accordance with Rule 10b5-1 for payment of withholding tax liability incurred upon the vesting of 20,711 restricted stock units, which were previously granted on March 17, 2016 and which vested on March 17, 2018. Read SEC document |
| September 28, 2017 Filed Oct 2, 2017 20:14 UTC | KALA BIO, Inc. KALA · Entity 7964 | GrantStock Option (right to buy) · Derivative | 25,920 | $0.00 Strike: $23.08 | $0.00 |
DisclosureSEC source: 0001179110-17-012839 · edgar.xml · derivative · entry 1 KOVEN ANDREW I · CIK 0001258673 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,920 Underlying: Common Stock · 25,920 shares Expires 2027-09-28 F1 · derivative.exercise_date: This option was granted on September 28, 2017 and vests with respect to 1/3 of the shares on the first anniversary of the grant and with respect to an additional 1/36th of the shares on each monthly anniversary thereafter and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| June 05, 2017 Filed Jun 7, 2017 00:28 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | SaleCommon Shares, without par value | 161,906 | $1.28 | $207,110.16 |
DisclosureSEC source: 0001104659-17-037755 · a4.xml · nonDerivative · entry 1 KOVEN ANDREW I · CIK 0001258673 · President & Chief Business Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,363,695 F1 · kind: This represents shares sold by the issuer on behalf of the reporting person for payment of withholding tax liability incurred upon the vesting of 369,169 restricted stock units, which were previously granted on June 3, 2015 and which vested on June 3, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.2700 to $1.2900. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2017 Filed May 13, 2017 01:52 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | GrantEmployee Stock Option (right to buy) · Derivative | 126,158 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001104659-17-032413 · a4.xml · derivative · entry 2 KOVEN ANDREW I · CIK 0001258673 · President & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,158 Underlying: Common Shares, without par value · 126,158 shares Expires 2027-05-11 F3 · derivative.exercise_date: The option vests as to 25% of the shares on May 11, 2018, and the remainder vests in substantially equal monthly installments over the 36 months immediately following such date, subject to continued employment or service to the Company. Read SEC document |
| May 11, 2017 Filed May 13, 2017 01:52 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | GrantCommon Shares, without par value | 109,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-032413 · a4.xml · nonDerivative · entry 1 KOVEN ANDREW I · CIK 0001258673 · President & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,525,601 F1 · kind: Restricted Stock Units granted pursuant to the Aralez Pharmaceuticals Inc. 2016 Amended and Restated Long-Term Incentive Plan, which vest in substantially equal annual installments over the three years immediately following the date of grant, subject to continued employment or service to the Company. F2 · balance_after: Includes 267,483 shares of Common Stock and 1,258,118 Restricted Stock Units. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 20:17 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | SaleCommon Shares, without par value | 7,825 | $2.41 | $18,858.25 |
DisclosureSEC source: 0001104659-17-018599 · a4.xml · nonDerivative · entry 1 KOVEN ANDREW I · CIK 0001258673 · President & Chief Business Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,416,411 F1 · kind: This represents shares sold by the issuer on behalf of the reporting person pursuant to an instruction made in accordance with Rule 10b5-1 for payment of withholding tax liability incurred upon the vesting of 20,710 restricted stock units, which were previously granted on March 17, 2016 and which vested on March 17, 2017. F2 · price: This transaction was executed in two trades at prices of $2.4100 and $2.4101. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 20:17 UTC | Aralez Pharmaceuticals Inc. ARLZ · Entity 165961 | PurchaseCommon Shares, without par value | 20,000 | $2.55 | $50,920.00 |
DisclosureSEC source: 0001104659-17-017613 · a4.xml · nonDerivative · entry 1 KOVEN ANDREW I · CIK 0001258673 · President & Chief Business Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,424,236 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.525 to $2.560. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.